AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Sees Significant Drop in Short Interest

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totaling 913,892 shares, a decline of 40.8% from the July 15th total of 1,543,826 shares. Based on an average trading volume of 741,607 shares, the short-interest ratio is currently 1.2 days. Currently, 6.3% of the shares of the company are short sold.

AIM ImmunoTech Trading Down 5.3%

Shares of AIM ImmunoTech stock traded down $0.01 during trading on Tuesday, reaching $0.23. The company’s stock had a trading volume of 455,974 shares, compared to its average volume of 1,418,435. The business’s 50-day moving average price is $0.30 and its 200-day moving average price is $0.55. AIM ImmunoTech has a 52 week low of $0.19 and a 52 week high of $2.98.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.43) EPS for the quarter. The company had revenue of $0.03 million for the quarter. As a group, sell-side analysts forecast that AIM ImmunoTech will post -0.63 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in AIM ImmunoTech stock. DRW Securities LLC increased its holdings in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) by 60.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,545 shares of the company’s stock after buying an additional 26,254 shares during the period. DRW Securities LLC owned 2.12% of AIM ImmunoTech worth $79,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 12.02% of the company’s stock.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets lowered their target price on AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $9.00.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.